NasdaqGS:BBIOBiotechs
BridgeBio Pharma (BBIO) Is Up 5.8% After Advancing Encalaeret NDA And Late-Stage Rare-Disease Data
BridgeBio Pharma recently reported strong late-stage clinical data for acoramidis in transthyretin amyloid cardiomyopathy and encaleret in autosomal dominant hypocalcemia type 1, alongside submitting a New Drug Application to the FDA for encaleret.
These advances suggest BridgeBio is moving beyond a single-product story, with encaleret potentially adding a second rare-disease franchise alongside Attruby.
We’ll now examine how the positive encaleret NDA submission and ADH1 data could reshape...